Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydralazine
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dihydralazine is a prescription antihypertensive drug belonging to the hydrazinophthalazine chemical class. It acts primarily by combating the effects of adrenaline and expanding blood vessels (vasodilation), which lowers blood pressure and allows smoother blood flow. Its mechanism of action is similar to that of hydralazine, involving direct relaxation of vascular smooth muscle. Dihydralazine is generally administered orally in tablet form for the treatment of high blood pressure[1].
- Brand names
- NepresolPressreduct
- Other names
- 1,4-dihydrazinophthalazinedihydralazine sulfatedihydralazine mesylate
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on dihydralazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydralazine.